Skip to main content

Advertisement

Log in

Utilizing the Multiradionuclide Resolving Power of SPECT and Dual Radiolabeled Single Molecules to Assess Treatment Response of Tumors

  • Research Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Purpose

Single photon emission computed tomography (SPECT) radionuclide pairs having distinct decay rates and different energy maxima enable simultaneous detection of dual gamma signals and real-time assessment of dynamic functional and molecular processes in vivo. Here, we report image acquisition and quantification protocols for a single molecule labeled with two different radionuclides for functional SPECT imaging.

Procedures

LS370 and LS734 were prepared using modular solid phase peptide synthesis. Each agent has a caspase-3 cleavable reporting motif, flanked by a tyrosine residue and a chelator at the opposite end of molecule. Cell uptake and efflux were assessed in human MDA-MB-231 breast cancer cells. Biodistribution studies were conducted in tumor naive and orthotopic 4T1 metastatic breast cancer tumor mice. NanoSPECT dual-imaging validation and attenuation correction parameters were developed using phantom vials containing varying radionuclide concentrations. Proof-of-principle SPECT imaging was performed in MMTV-PyMT transgenic mice.

Results

LS370 and LS734 were singly or dually radiolabeled with 125I and 111In or 99mTc. Cell assays demonstrated 11-fold higher percent uptake (P < 0.001) of [125I]LS734 (3.6 ± 0.5) compared to [125I]LS370 (0.3 ± 0.3) at 2 h. Following chemotherapy, cellular retention of [125I]LS734 was 3-fold higher (P < 0.05) than untreated cells. Pharmacokinetics at 1 h postinjection demonstrated longer blood retention (%ID/g) for [125I]LS734 (3.2 ± 0.9) compared to [125I]LS370 (1.6 ± 0.1). In mice bearing bilateral orthotopic 4T1 tumors, the uptake (%ID/g) was 2.4 ± 0.3 for [125I]LS734 and 1.2 ± 0.03 for [125I]LS370. The iodinated tyrosine peptide residue label was stable under in vitro conditions for up to 24 h; rapid systemic deiodination (high thyroid uptake) was observed in vivo. Phantom studies using standards demonstrated deconvolution of radionuclide signals based on different gamma ray energies. In MMTV-PyMT mice imaged with dual-labeled [111In]–[125I]LS734, the gamma signals were separable and quantifiable.

Conclusions

Image processing protocols were developed for quantitative signal separation resulting from a caspase-3 responsive dual-radiolabeled SPECT probe. Crosstalk unmixing was obtained for multiradionuclide NanoSPECT imaging. In vitro and in vivo data demonstrated structure–activity relationships for developing functional agents for ratiometric SPECT imaging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Choi KY, Swierczewska M, Lee S, Chen X (2012) Protease-activated drug development. Theranostics 2:156–178

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Boya P, Kroemer G (2008) Lysosomal membrane permeabilization in cell death. Oncogene 27:6434–6451

    Article  CAS  PubMed  Google Scholar 

  3. Johansson AC, Appelqvist H, Nilsson C et al (2010) Regulation of apoptosis-associated lysosomal membrane permeabilization. Apoptosis 15:527–540

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Graham MM (2012) Clinical molecular imaging with radiotracers: current status. Med Princ Pract: Int J Kuwait University, Health Sci Centre 21:197–208

    Article  Google Scholar 

  5. Benard F, Turcotte E (2005) Imaging in breast cancer: single-photon computed tomography and positron-emission tomography. Breast Cancer Res 7:153–162

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Chen DL, Zhou D, Chu W et al (2012) Radiolabeled isatin binding to caspase-3 activation induced by anti-Fas antibody. Nucl Med Biol 39:137–144

    Article  PubMed Central  PubMed  Google Scholar 

  7. Beekman F, van der Have F (2007) The pinhole: gateway to ultra-high-resolution three-dimensional radionuclide imaging. Eur J Nucl Med Mol Imaging 34:151–161

    Article  PubMed  Google Scholar 

  8. Edwards WB, Akers WJ, Ye Y et al (2009) Multimodal imaging of integrin receptor-positive tumors by bioluminescence, fluorescence, gamma scintigraphy, and single-photon emission computed tomography using a cyclic RGD peptide labeled with a near-infrared fluorescent dye and a radionuclide. Mol Imaging 8:101–110

    PubMed Central  CAS  PubMed  Google Scholar 

  9. Yang TJ, Haimovitz-Friedman A, Verheij M (2012) Anticancer therapy and apoptosis imaging. Exp Oncol 34:269–276

    PubMed  Google Scholar 

  10. Wang J, Lenardo MJ (2000) Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci 113(Pt 5):753–757

    CAS  PubMed  Google Scholar 

  11. Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281:1305–1308

    Article  CAS  PubMed  Google Scholar 

  12. Zhang Z, Fan J, Cheney PP et al (2009) Activatable molecular systems using homologous near-infrared fluorescent probes for monitoring enzyme activities in vitro, in cellulo, and in vivo. Mol Pharmaceutics 6:416–427

    Article  CAS  Google Scholar 

  13. Ma CX, Cai S, Li S et al (2012) Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Investig 122:1541–1552

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Bullok KE, Maxwell D, Kesarwala AH et al (2007) Biochemical and in vivo characterization of a small, membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. Biochemistry 46:4055–4065

    Article  CAS  PubMed  Google Scholar 

  15. Eckelman WC, Bonardi M, Volkert WA (2008) True radiotracers: are we approaching theoretical specific activity with Tc-99m and I-123? Nucl Med Biol 35:523–527

    Article  CAS  PubMed  Google Scholar 

  16. Chau I, Rigg A, Cunningham D (2003) Matrix metalloproteinase inhibitors—an emphasis on gastrointestinal malignancies. Crit Rev Oncol Hematol 45:151–176

    Article  PubMed  Google Scholar 

  17. Luker GD, Luker KE (2008) Optical imaging: current applications and future directions. J Nucl Med 49:1–4

    Article  PubMed  Google Scholar 

  18. Ntziachristos V, Bremer C, Graves EE, Ripoll J, Weissleder R (2002) In vivo tomographic imaging of near-infrared fluorescent probes. Mol Imaging 1:82–88

    Article  PubMed  Google Scholar 

  19. Bremer C, Tung CH, Weissleder R (2001) In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 7:743–748

    Article  CAS  PubMed  Google Scholar 

  20. Glazer DI, Brown RK, Wong KK, Savas H, Gross MD, Avram AM (2013) SPECT/CT evaluation of unusual physiologic radioiodine biodistributions: pearls and pitfalls in image interpretation. Radiographics 33:397–418

    Article  PubMed  Google Scholar 

  21. van Schaijk FG, Broekema M, Oosterwijk E et al (2005) Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting. J Nucl Med 46:1016–1022

    PubMed  Google Scholar 

Download references

Acknowledgments

We thank Rui Tang, Kvar Black, and Mingzhou Zhou for helpful discussions.

Funding

This work was funded primarily by grant from the Department of Defense Breast Cancer Research Program (W81XWH-09-1-0333) and supported in part by grant from the National Institutes of Health NIBIB R01 EB021048 and resources from the Washington University Molecular Imaging Center (NCI P50 CA094056). WJA is supported in part by an award from the NIH Office of Research Infrastructure Programs (K01RR026095). MS is supported in part by an R01 award from NIH (R01CA176221).

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of Interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Samuel Achilefu.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 398 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, B., Shokeen, M., Sudlow, G.P. et al. Utilizing the Multiradionuclide Resolving Power of SPECT and Dual Radiolabeled Single Molecules to Assess Treatment Response of Tumors. Mol Imaging Biol 17, 671–679 (2015). https://doi.org/10.1007/s11307-015-0842-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-015-0842-8

Key words

Navigation